Modeling studies of the impact of microbicides between 2008-2016
Topic(s): Research
Product(s): Dapivirine Vaginal Ring
Population(s): Cisgender Women
Format(s): Spreadsheet
Source(s): N/A
Type: Document
This suite of clinical reporting forms, developed by South Africa’s National Department of Health, can be used for PrEP reporting, including injectable lenacapavir (LEN). The download folder includes forms for PrEP initiation, continuation, pregnancy outcome reporting, and seroconversion reporting.
These country profiles provide concise, actionable snapshots of the HIV prevention and treatment landscape for key populations across multiple countries, including: Brazil, Eswatini, France, Kenya, Malawi, Mozambique, Nigeria, the Philippines, South Africa, Uganda, Ukraine, the United States, Vietnam, Zambia, and Zimbabwe. Country profiles highlight: History of PrEP introduction Updates on PrEP Products Key population epidemiology…
This dashboard, produced under the BioPIC project, reflects all currently known activities relating to implementation research, modelling, clinical research, and landscaping for new late stage biomedical HIV PrEP options, including lenacapavir for PrEP, cabotegravir, and the dapivirine vaginal ring. To update or add any activities missing from the dashboard, or if you have questions on…
AVAC’s Country Planning for Product Introduction Matrix tracks key indicators for the introduction of new PrEP products, including lenacapavir (LEN), cabotegravir (CAB), and the Dapivirine Vaginal Ring (DVR), by country, including regulatory status, late stage clinical trials and implementation research, procurement plans, and recent oral PrEP provision.
These guidelines, produced in 2022 by the Uganda Ministry of Health, provide guidance on the diagnosis of HIV, the care of people living with HIV, and the use of antiretroviral drugs for treating and preventing HIV infection, including injectable cabotegravir and the dapivirine vaginal ring.
The document, produced by the Malawi Ministry of Health, is a guideline to support funders, implementing partners, district health team leads and service providers in implementing Oral and Long-Acting Injectable PrEP in Malawi.
This article from AIDS and Behavior explores preferences for various long-acting PrEP modalities amongst pregnant and lactating people in Botswana and South Africa. It further examines participants’ HIV risk perception during pregnancy and breastfeeding, their perceived individual-level facilitators and barriers of each PrEP modality, and the support needed by participants for PrEP uptake and continuation.
This toolkit is designed to help clinicians develop knowledge and skills to provide multiple HIV PrEP methods. The toolkit includes resources for oral PrEP, long-acting cabotegravir (CAB-LA), dapivirine vaginal ring (DVR), and long-acting lenacapavir (LEN). Click here to download the full set of additional resources for this training. In October 2025, Jhpiego and WHO held…
This special JIAS supplement illustrates current evidence, implementation learnings and challenges associated with the introduction, uptake, and continued use of PrEP within the context of an expanded HIV prevention method-mix.
This article from PLOS Global Public Health describes the results of a study assessing the acceptability and feasibility of introducing the dapivirine vaginal ring (DVR) as an HIV prevention method among young women in Zimbabwe and to assess motivations and barriers of DVR uptake among the target population.